|Articles|September 22, 2016

EpiPen Controversy: Mylan CEO Faces Congressional Committee

September 22, 2016

Mylan CEO Heather Bresch appeared before the House Committee on Oversight and Government Reform on Sept. 21, 2016 to explain the company’s decision to increase the price of EpiPen more than 400%. The meeting comes after multiple members of Congress raised concerns about the price of the life-saving drug, which is used to treat anaphylaxis.

In her pre-released testimony, Bresch attempted to clarify exactly how much money Mylan makes off each EpiPen sale.

For the rest of this news release, see Pharmaceutical Technology.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

EpiPen Controversy: Mylan CEO Faces Congressional Committee

Newsletter

Related Content

Aidoc Submits Breakthrough-Designated Multi-Triage Device for FDA Approval

How Technology is Moving the Industry Away from Animal Testing: Q&A with Dr. Jo Varshney

Agentic AI Will Transform the Business of Life Sciences

Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity

Lilly Forms Partnership with NVIDIA to Create AI Supercomputer

Trending on PharmExec

Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion

FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma

FDA Appoints Tracy Beth Høeg as Acting Director of CDER

Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER

Five Steps for Successful CGT Commercialization Through Health Systems Partnerships